Allergic Rhinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Document Sample
Allergic Rhinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Powered By Docstoc
					Allergic Rhinitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018

The Allergic Rhinitis Therapeutics Market is Forecast to Decline until 2018

GlobalData’s analysis estimated the allergic rhinitis therapeutics market (the US, the UK, France,
Germany, Italy, Spain and Japan) to be worth $4,406.6m in 2010. It is forecast to decline at a Compound
Annual Growth Rate (CAGR) of 1.3% for the next eight years to reach $3,981.0m by 2018. The market
declined during 2005–2010 owing to the patent expiries of major drugs such as Zyrtec (cetirizine) and
Omnaris (ciclesonide) in 2007 and 2010 respectively. The decline during the forecast period can be
attributed to the expected patent expiry of Astelin (azelastine hydrochloride), Nasonex (mometasone
furoate), Nasacort AQ (triamcinolone acetonide) and Rhinocort Aqua (budesonide) in the year 2011,
2014, 2016 (US) and 2017 respectively. Nasacort AQ will loose its patent protection in the Europe in
2017. In addition, Astepro (azelastine hydrochloride), Xyzal (levocetirizine) and Singulair (montelukast
sodium) are set to loose their patent protection in the year 2012.

This decline in the market can be slightly offset by the expected launch of Dymista (combination of
azelastine hydrochloride and fluticasone propionate), Omnaris HFA (ciclesonide nasal aerosol in a
hydrofluoroalkane (HFA) formulation) and Qnaze HFA (beclomethasone dipropionate
hydrofluoroalkane) in the year 2012. The expected launch of a novel immunotherapeutic agent, Actair
(house dust mite desensitization tablet) might have a significant impact on the market

The allergic rhinitis therapeutics market is currently dominated by branded drugs, generics and over-
thecounter (OTC) medications. These drugs aim at providing symptomatic relief for allergic rhinitis.
Intranasal corticosteroids and antihistamine classes of drugs constitute the mainstay of the modern
management of allergic rhinitis. Intranasal corticosteroids and antihistamines are considered as the first-
line and secondline treatment option respectively for moderate to severe allergic rhinitis. These drugs
have proven to be efficacious and safe for the treatment of allergic rhinitis and therefore, the allergic
rhinitis therapeutics market is well served by these approved drugs. The only limitation of these drugs is
that they do not target the root-cause of the disease. Therefore, innovative immunotherapies acting as
the disease-modifying agents can gain a significant market share.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Allergic-Rhinitis-Therapeutics-
Pipeline-Assessment-and-Market-Forecasts-to-
2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=dcsto

GlobalData’s analysis shows that immunotherapeutic products in development constitute 21% of the
total 2011 allergic rhinitis pipeline and the immunotherapeutic class is largely focused on the oral
sublingual tablet formulations. As immunotherapy is the only treatment option for allergic rhinitis with a
diseasemodifying potential, large-scale development programs are being conducted which are primarily
driven by new guidelines and changing regulations. Therefore, these innovative therapies are expected
to promote the growth of allergic rhinitis therapeutics market in the future.

GlobalData, the industry analysis specialist, has released its new report, “Allergic Rhinitis Therapeutics -
Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information
and analysis on the global allergic rhinitis therapeutics market, identifying the key trends shaping and
driving the market. The report also provides insights on the prevalent competitive landscape and the
emerging players expected to significantly alter the market positioning of the current market leaders.
Most importantly, the report provides valuable insights on the pipeline products within the global
allergic rhinitis therapeutics sector. This report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of
industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Allergic-Rhinitis-Therapeutics-Pipeline-
Assessment-and-Market-Forecasts-to-
2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Health
ca&CompanyID=dcsto

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe:                +44 207 753 4299
                       +44 1204 543 533
Asia Pacific:          +91 40 6616 6782

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:9
posted:12/2/2011
language:English
pages:2
Description: The Allergic Rhinitis Therapeutics Market is Forecast to Decline until 2018